Epinephrine inhalation - G2B Pharma/Shin Nippon Biomedical Laboratories

Drug Profile

Epinephrine inhalation - G2B Pharma/Shin Nippon Biomedical Laboratories

Alternative Names: G2B-011

Latest Information Update: 26 Aug 2014

Price : $50

At a glance

  • Originator G2B Pharma; Shin Nippon Biomedical Laboratories
  • Class Antiarrhythmics; Antihaemorrhagics; Antihypotensives; Bronchodilators; Catecholamines; Ethanolamines; Small molecules
  • Mechanism of Action Adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Anaphylaxis

Most Recent Events

  • 13 Aug 2014 Sosei receives first right to negotiate for global licensing of epinephrine inhalation
  • 26 Sep 2013 Research programme: Epinephrine inhalation - G2B Pharma/Shin Nippon is available for licensing as of 26 Sep 2013. http://www.snbl-nds.co.jp/en/
  • 10 Sep 2013 Preclinical trials in Anaphylaxis in Japan (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top